# Panome Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/panome-bio

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.panomebio.com
- Total disclosed funding: $6M
- Latest round: Series A (Feb 15, 2023)
- Investors on record: 2

## About

Based in Missouri, US, and founded in 2022 by its Chief Scientific Officer, Gary J. Patti, and co-founders, Edward Weinstein, and Tom Cohen, Panome Bio Inc., operates as a biomarker discovery platform that offers various biomarker analysis, including metabolomics, lipidomic, and proteomics screening solutions. In March 2023, Panome Bio raised USD 5.97 in growth capital funding, led by investor Telegraph Hill Partners.

Panome Bio offers various metabolomics, lipidomics, and proteomics screening services that include lipid analysis, isotope-tracer analysis, mapping drug targets, and longitudinal analysis, along with a detailed report. The company’s platform also provides sample testing for serum and plasma, cell pellets, tissue sections, and other biofluids from multiple organisms.

The company plans to use the March 2023 funding to develop new technologies and capabilities, expand laboratory facilities, and grow its team to service the increasing interest in metabolomics and proteomics data.

## Funding rounds

- Series A, Feb 15, 2023, $6M — Telegraph Hill Partners, BioGenerator

## Investors

- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series A
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series A